Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective

Haemophilia

Volumn 9, Issue SUPPL. 1, 2003, Pages 101-110

  Bjorkman S ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Dosing; Factor IX; Factor VIII; Haemophilia; Pharmacokinetics; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ARTICLE; CALCULATION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; HEALTH ECONOMICS; HEMOPHILIA; HUMAN; IN VIVO STUDY; INDIVIDUALIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0037764674     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.9.s1.4.x     Document Type: Article

References (56)

1. Nilsson IM, Blombäck M, Ahlberg Å. Our experience in Sweden with prophylaxis on haemophilia. Proceedings of the 5th Congress of the World Federation of Hemophilia, Montreal 1968; Bibl Haematol, No. 34. New York: Karger, 1970; 111-24.
2. Nilsson IM, Hedner U, Ahlberg Å. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129-35.
3. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
4. Berntorp E. Methods of haemophilia care delivery: regular prophylaxis versus episodic treatment. Haemophilia 1995; 1 (Suppl. 1): 3-7.
5. Ljung RCR. Prophylactic treatment in Sweden - overtreatment or optimal model? Haemophilia 1998; 4: 409-12.
6. Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand 1962; 171: 237-42.
7. Ahlberg Å. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthopaedica Scand 1965; (Suppl. 77): 1-98.
8. Mannucci PM, Mendolicchio L, Gringeri A. Use of prophylaxis to prevent complications of hemophilia. Adv Exp Med Biol 2001; 489: 59-64.
9. Kasper CK, Dietrich SL, Rapaport SI. Hemophilia prophylaxis with factor VIII concentrate. Arch Int Med 1970; 125: 1004-9.
10. Morfini M, Mannucci PM, Mariani G et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scand J Haematol 1976; 16: 41-7.
11. Schimpf K, Fischer B, Rothmann P. Die ambulante Dauerbehandlung der Hämophilie A. Eine kontrollierte Studie. Dtsch Med Wochenschr 1976; 101: 141-8.
12. Schimpf K, Fischer B, Rothmann P. Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study. Scand J Haematol 1977; (Suppl. 30): 79-80.
13. Aronstam A, Kirk PJ, McHardy J et al. Twice weekly prophylactic therapy in haemophilia A. J Clin Pathol 1977; 30: 65-7.
14. Aronstam A, McLellan DS, Turk P. Transfusion requirements of adolescents with severe haemophilia A. J Clin Pathol 1979; 32: 927-30.
15. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
16. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
17. Skolnick AA. Hemophilia foundation recommends prophylactic use of clotting factors. JAMA 1994; 272: 1153-4.
18. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998; 4: 413-7.
19. Ljung R, Aronis-Vournas S, Kurnik-Auberger K et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 2000; 6: 619-24.
20. Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol 1973; 24: 539-51.
21. Aledort LM, Haschmeyer RH, Pettersson H and the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994; 236: 391-9.
22. Ghosh K, Shetty S, Mohanty D. Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay. Haemophilia 2001; 7: 9-12.
23. van den Berg HM, Fisher K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
24. 10400 → T) and heterozygous factor V Leiden. Haemophilia 2001; 7: 511-4.
25. Walsh PN, Rainsford SG, Biggs R. Platelet coagulant activities and clinical severity in haemophilia. Thrombos Diathes Haemorrh 1973; 29: 722-9.
26. Arbini AA, Mannucci PM, Bauer KA. Low prevalence of the factor V Leiden mutation among 'severe' hemophiliacs with a 'milder' bleeding diathesis. Thromb Haemost 1995; 74: 1255-8.
27. Lee DH, Walker IR, Teitel J et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost 2000; 83: 387-91.
28. Escuriola Ettingshausen C, Halimeh S, Kurnik K et al. Symptomatic onset of severe haemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85: 218-20.
29. Carlsson M, Berntorp E, Björkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.
30. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001; 7: 99-102.
31. Carlsson M, Björkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia 1998; 4: 83-8.
32. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosage in prophylaxis. Haemophilia 2001; 7: 133-9.
33. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
34. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
35. van Den Berg HM, Fischer K, van Der Bom JG, Roosendaal G, Mauser-Bunschoten EP. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia 2002; 8 (Suppl. 2): 43-6.
36. Björkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia 1997; 3: 1-8.
37. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokin 2001; 40: 815-32.
38. Matucci M, Messori A, Donati-Cori G et al. Kinetic evaluation of four factor VIII concentrates by model-independent methods. Scand J Haematol 1985; 34: 22-8.
39. Fijnvandraat K, Peters M, Ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474-6.
40. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group 0 than in those with blood group A. Thrombos Haemostas 2000; 83: 65-9.
41. White G, Shapiro A, Ragni M et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35 (Suppl. 2): 33-8.
42. Carlsson M, Berntorp E, Björkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51: 247-52.
43. Duncan B, Lloyd J, Lesnikowski E. Successive factor VIII doses for a haemophiliac undergoing major surgery calculated on a microcomputer. Thrombos Haemostas 1982; 47: 66-8.
44. Longo G, Matucci M, Morfini M, Vannini S, Messori A. A calculator program for individualizing factor VIII dosage. Drug Intell Clin Pharm 1984; 18: 726-30.
45. Messori A, Longo G, Matucci M, Morfini M, Rossi Ferrini PL. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin Pharmacokinet 1987; 13: 365-80.
46. Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294-305.
47. Ruffo S, Messori A, Grasela TH et al. A calculator program for clinical application of the Bayesian method of predicting plasma drug levels. Comput Progr Biomed 1985; 19: 167-77.
48. Kasper CK. Problems with the potency of factor VIII concentrate. New Engl J Med 1981; 305: 50-1.
49. Rock G, Tittley P, Fuller V. An in vivo assessment of factor VIII concentrates. JAMA 1985; 254: 777-80.
50. Allain J-P, Frommel D. Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A. Blood 1976; 47: 973-82.
51. Allain J-P. Principles of in vivo recovery and survival studies. Scand J Haematol 1984; 33 (Suppl. 41): 123-30.
52. Peerlink K, Arnout J, Di Giambattista M et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
53. Longo G, Matucci M, Messori A, Morfini M, Rossi-Ferrini P. Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods. Thromb Res 1986; 42: 471-6.
54. Kasper CK. In vivo recovery and early half-life of infused factor VIII in haemophilia A. Haemophilia 1995; 1: 14-6.
55. Dazzi F, Tison T, Vianello F et al. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 1996; 93: 688-93.
56. Björkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994; 325-32.